Original news and analysis on international IP policy
the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) provided its recommendations on how to slow down antimicrobial resistance and boost antibiotic research and development. In addition, the association organised a forum on the subject today.
In Chile, pharmaceutical patents are almost exclusively the domain of foreign companies. Only a subset of drugs is protected by patents, while a much larger number of products is protected by trademarks, a study finds, offering for the first time empirical evidence on the use of primary and secondary patents in Chile.
The World Health Organization released a report today on countries’ response to the global declining effect of antibiotics on bacteria and microbes, heightened by overuse or misuse of those products. Next month the World Health Assembly will consider a draft global action plan to fight the problem, which includes suggestions for sustainable investment in the area such as de-linking research from price and sales, as well as equitable access to new products.
Universities play an enormous role in biomedical research in the United States, but are not doing all they can to advance research for neglected diseases or make their innovations available to people who need them most, the student groupUniversities Allied…
Burcu Kilic & Pablo Viollier write: Political leaders in Washington and other Trans-Pacific Partnership (TPP) negotiating countries have set the end of May as the latest deadline for completion of the talks. The negotiations have already missed several such deadlines, so who really knows? No one. But there is something we all know: TPP raises significant concerns because negotiations are being held behind closed doors with details kept secret even from the legislatures in TPP countries.
A newly announced project will create an open, online database of information about the clinical research trials worldwide. The initiative, called Open Trials, will be directed by Ben Goldacre, an internationally known author (“Bad Science”) and advocated for clinical transparency.…
The World Health Organization is reviewing its list of essential medicines this week. Over 70 candidate medicines are expected to be assessed by an Expert Committee. Some of those medicines are under patent and highly priced, which poses an accessibility challenge.
The World Health Organization has announced that its Global Medicines Safety Database is now open to the general public. The database named VigiAccess can now be accessed on any computer or smartphone in the world.
CAPE TOWN - Pharmaceutical patents and access to medicines was the focus of an animated panel discussion by experts offering divergent views on the topic at intellectual property group FICPI’s 2015 World Congress, currently underway in Cape Town, South Africa.
The World Health Organization today issued a call for disclosure of results from clinical trials for medical products, no matter what the results of the trials were. And a variety of events and publications are addressing medicines access today.
The World Health Organization has issued a guidance document on the design of bioequivalence studies for a leading hepatitis C medicine. Generic drug companies seeking prequalification by the WHO need to demonstrate that their generic version is equivalent to the originator drug.
The IDA Foundation, a worldwide supplier of essential medicines to low-and medium income countries, has backed the request by least-developed countries to extend a waiver that allows them to forfeit the obligations to protect intellectual property on pharmaceutical products. UNITAID, the UN-related drug purchasing mechanism, also issued a statement in support of the extension. The request is expected to be discussed at the World Trade Organization in June.